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Disaccharides obtained from 
carrageenans as potential 
antitumor agents
Gustavo H. Calvo1, Vanina A. Cosenza2, Daniel A. sáenz1, Diego A. Navarro2, Carlos A. stortz2, 
Mariela A. Céspedes1, Leandro A. Mamone1, Adriana G. Casas1 & Gabriela M. Di Venosa1
Carrageenans are sulfated galactans found in certain red seaweeds with proven biological activities. 
In this work, we have prepared purified native and degraded κ-, ι-; and λ-carrageenans, including the 
disaccharides (carrabioses) and disaccharide-alditols (carrabiitols) from seaweed extracts as potential 
antitumor compounds and identified the active principle of the cytotoxic and potential antitumor 
properties of these compounds. Both κ and ι-carrageenan, as well as carrageenan oligosaccharides 
showed cytotoxic effect over LM2 tumor cells. Characterized disaccharides (carrabioses) and the 
reduced product carrabiitols, were also tested. Only carrabioses were cytotoxic, and among them, 
κ-carrabiose was the most effective, showing high cytotoxic properties, killing the cells through an 
apoptotic pathway. In addition, the cells surviving treatment with κ-carrabiose, showed a decreased 
metastatic ability in vitro, together with a decreased cell-cell and cell-matrix interactions, thus 
suggesting possible antitumor potential. Overall, our results indicate that most cytotoxic compounds 
derived from carrageenans have lower molecular weights and sulfate content. potential applications 
of the results emerging from the present work include the use of disaccharide units such as carrabioses 
coupled to antineoplasics in order to improve its cytotoxicity and antimetastatic properties, and the use 
of ι-carrageenan as adjuvant or carrier in anticancer treatments.
For decades, red seaweeds have been an important source of hydrocolloids (i.e. carrageenans and agarans), widely 
used both in food and non-food industries1. Carrageenans, in particular, are sulfated galactans with a backbone 
of [ → 3)-β-d-Galp-(1 → 4)-α-d-Galp-(1 → ] and differ from each other in monosaccharide composition, degree 
and positions of sulfate groups, possible replacement of the α-galactose unit (G) by a 3,6-anhydrogalactose moi-
ety (A) and molecular weights. Classification of these galactans depends on the presence or absence of the anhy-
dro sugar and the position of the sulfate groups.
Three carrageenan types, so-called κ-, ι- and λ-carrageenans, are of commercial significance. These carrageen-
ans are attractive due to their rheological properties as stabilizers and thickening or gelling agents2. Both κ- and 
ι-carrageenans can form gels upon cooling or in the presence of K+ or Ca2+ counterions3, whereas λ-carrageenan 
hardly gels, or needs high concentrations of K+ to give weak gels4,5. Thus, it is used as a thickening agent6. They 
can be used in the food, pharmaceutical, cosmetics, printing and textile industries. In addition, it was reported 
their use as renewable, ecological and nontoxic mobility control agents to increase sweep efficiency for oil recov-
ery in dwindling petroleum reserves7.
Besides their commercial interest, carrageenans are also known to have biological properties as well as low 
toxicity. These properties are originated in their negative charge and their resemblance to the glycosaminoglycans 
(GAGs) present in the cell membranes of mammals8. The antiviral activity is the most studied biological property 
and it is attributed to the capacity of the sulfated polysaccharides to hinder the viral entry to the host9. Several 
reports have shown the effectiveness of carrageenans against different enveloped and non-enveloped viruses9. 
Actually, it was observed that high molecular weight and high degrees of sulfation favor the antiviral activity8.
The antitumor activity of carrageenans has been less explored. Nonetheless, it is an area of great potential10. 
The antitumor activity of these polysaccharides could be related to the destabilization of the interaction of the 
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GAG portion of the proteoglycans and the extracellular matrix proteins, thus eliminating the adhesion of cancer 
cells to matrices, which is necessary in metastasis spread11.
λ-Carrageenan from Chondrus ocellatus12, κ-carrageenan from Kappaphycus alvarezii13 as well as commer-
cial κ- and λ-carrageenan14,15 showed antitumor activity in vivo and/or cytotoxic activity in vitro. They possess 
either a direct inhibitory action on cancer cells and tumors or influence different stages of carcinogenesis and 
tumor development, recover the broken balance between proliferation and programmed cell death (apoptosis) 
and are useful for cancer prevention16. Actually, the polysaccharide isolated from C. ocellatus was only active in 
vivo, probably related to immunomodulating activity of the galactan. Due to its unique secondary and tertiary 
structure, carrageenan is resistant to biochemical degradation by lysosomal glycosidases. Carrageenan containing 
phagolysosomes eventually rupture due to osmotic swelling. The consequent release of hydrolytic enzymes into 
the cytosol causes irreversible damage and eventual lysis of macrophages17.
Taking into consideration the scarcity of structural analysis performed to the antitumor agents12,13,18, few 
correlations have been observed between the chemical structure and the antitumor activity. Nonetheless, it was 
observed that depolymerization of carrageenans (mainly κ-, ι- and λ-carrageenan) favors their antitumor activ-
ity11,12,18–21. Actually, when oligosaccharides of different molecular weights were evaluated, those with the lowest 
values showed higher activity12,18,21. Interestingly, there are no reports of the antitumor activity of the isolated 
disaccharidic units, i.e. carrabiose or neocarrabiose.
In most cases, anticancer activity was only observed in vivo11,12,19 though in vitro cytotoxicity of degraded 
κ- and ι-carrageenan was also observed18,21.
Nowadays, almost 75% of the anticancer agents used in chemotherapy are derived from natural sources, and 
plants are an important source of new promising therapies22.
As carbohydrates are involved in tumor development, progression, invasion and metastasis, glycan struc-
tural abnormalities were always considered as golden bio-marks to diagnose and rank cancer status23, so car-
bohydrates including mono- or disaccharides were incorporated to non-specific antitumor molecules in order 
to improve the targeting and efficacy properties. The disaccharide moiety of bleomycin (BLM), composed of 
3-O-carbamoyl-D-mannose and L-gulose, was employed to improve targeting of tumor cells is one of the recently 
employed strategies24.
In addition, research on marine polysaccharide-based nanomaterials is emerging in nanobiotechnological 
fields such as drug delivery25. Both chitosan and carrageenan are marine-derived polymers which have demon-
strated to assemble into nanoparticles26, and κ- and λ- (but not ι-carrageenans) have been employed as carriers of 
anticancer drugs27 and as adjuvants on the preparation of dendritic based vaccines for cancer treatment15.
The aim of the present work, was to study purified native and degraded carrageenans, and their disaccharides, 
obtained from extracts from Hypnea musciformis, Iridaea undulosa and Euchema spinosum (Fig. 1) as potential 
cytotoxic and antitumor compounds.
Materials and Methods
Chemicals. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide (MTT) and ι-carrageenan 
(Fig. 2A) from Euchema spinosum (460 kDa) were obtained from Sigma-Aldrich (Poole, UK). The rest of the 
chemicals employed were of analytical grade.
Material. Samples of Hypnea musciformis (Wulfen) Lamoroux Foslie were collected near Natal (Rio Grande 
do Norte), Brazil (5°37′52′′S, 35°13′03′′W). Samples of Iridaea undulosa were collected near Puerto Madryn 
(Province of Chubut), Argentina, and sorted at the Centro National Patagónico (Puerto Madryn, Chubut). The 
seaweeds were sorted, air dried, cleaned manually and milled to a fine powder before extraction.
extraction and fractionation. The extraction of the carrageenans from Hypnea muscifomis and KCl frac-
tionation procedures were described elsewhere6. A κ-carrageenan (215 kDa) (Fig. 2A,Ba) was obtained after pre-
cipitating the polysaccharides extracted in hot water with 0.125 M KCl, dialyzing and lyophilizing.
The extraction and fractionation of the carrageenans from Iridaea undulosa (both tetrasporic and cystocarpic) 
were also described elsewhere5. Extraction at room temperature of the cystocarpic samples gave a κ/ι/μ/ν-hybrid 
which, after alkaline treatment, yielded a κ/ι-hybrid carrageenan28. Room-temperature extraction of the tet-
rasporic plant afforded a λ-carrageenan (619 kDa) which was further purified by precipitation with KCl (fraction 
precipitated between 1 M and 1.25 M, Fig. 2A).
Generation of oligosaccharides from κ-carrageenan. Oligosaccharide with n = 25.5. One hundred 
mg of κ-carrageenan from H. musciformis were dissolved in 5 ml of water and eluted through an Amberlite IR-120 
column (H+ form) in order to obtain the acid form. Thirty ml were collected in an ice bath. The acid solution was 
heated at 60 °C for 6 h29. The solution was cooled, neutralized using NaHCO3 (ss), dialyzed (cut-off 1,000) and 
freeze-dried, yielding the corresponding oligosaccharide with a mean number of disaccharidic units (n) = 25.5 
(determined from its molecular weight of 10.4 kDa, Fig. 2A,Bb).
Oligosaccharide with n = 6.5. One hundred mg of the κ-carrageenan were treated with 25 ml 0.1 M trifluoro-
acetic acid (TFA) at 80 °C for 0.5 h. The solution was neutralized using NaHCO3 (ss), dialyzed (cut-off 1,000) and 
freeze-dried, yielding an oligosaccharide with a mean number of disaccharidic units (n) = 6.5 (determined by 
1H-NMR, Fig. 2A,Bc).
Generation of an oligosaccharide from λ-carrageenan. One hundred mg of λ-carrageenan from 
Iridaea undulosa were treated with 25 ml of 0.1 M TFA at 80 °C for 3 h. Then, the solution was neutralized using 
NaHCO3 (ss), dialyzed (cut-off 3,500) and freeze-dried obtaining an oligosaccharide with a mean number of 
disaccharide units (n) = 43.2 (determined from its molecular weight of 27.2 kDa, Fig. 2A).
3Scientific RepoRts |          (2019) 9:6654  | https://doi.org/10.1038/s41598-019-43238-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Generation of κ-carrabiose. One hundred mg of κ-carrageenan from H. musciformis were treated with 
25 ml of 0.1 M TFA at 80 °C for 3 h. The solution was evaporated at reduced pressure. The solid stuck into the 
vessel walls was redissolved in water and reevaporated, repeating the procedure three times in order to eliminate 
the TFA. Finally, the hydrolysis product was dissolved in water and freeze dried affording an impure κ-carrabiose 
(minor presence of oligosacharides with n ≥ 2 and monosaccharides was confirmed by NMR, representing less 
than 20% of the product, Fig. 2Bd).
The impure product was further purified by gel permeation chromatography using Biogel P2 as stationary 
phase (on a column of 30 cm × 1.5 cm), eluted with plain water. Glucose and blue dextran were used as markers of 
the Vf and V0 respectively. The sample (30 mg) was applied in 1 ml of distilled water, and fractions of 2 ml were col-
lected and analyzed using the phenol-H2SO4 method30. Fractions corresponding to the major peak were pooled 
and freeze-dried yielding pure κ-carrabiose (Fig. 2A). 1H-NMR signals (500 MHz, Fig. 2Be): δ = 5.00 (A-1), 4.67 
(G-4), 4.54 (G-1), 4.49 (A-5), 4.28 (A-4), 4.08 (A-3), 4.02 (A-6), 3.87 (G-5), 3.85 (A-6′), 3.82 (G-6,6′), 3.81 (G-3), 
3.64 (A-2), 3.56 (G-2). 13C-NMR signals (125 MHz): 104.0 (G-1), 90.7 (A-1), 87.9 (A-4), 83.3 (A-3), 77.3 (G-4), 
76.2 (A-5), 75.4 (G-5), 73.7 (A-2), 73.6 (A-6), 72.4 (G-3), 71.6 (G-2), 61.8 (G-6).
Generation of ι-carrabiose. ι-Carrabiose (Fig. 2A) was generated and purified using the same procedure 
depicted for κ-carrabiose (section 2.6) starting from a commercial ι-carrageenan. During the purification step, 
two fractions were isolated: a major one composed mainly of ι-carrabiose (Fig. 2A) and a minor one composed 
of a mixture of κ- and ι-carrabiose in 3:1 ratio (as determined by 1H-NMR). More than one purification step was 
necessary for isolating pure ι-carrabiose. 1H-NMR signals for purified ι-carrabiose (500 MHz): 5.26 (A-1), 4.67 
(G-4), 4.57 (G-1), 4.47 (A-5), 4.44 (A-4), 4.42 (A-2), 4.19 (A-3), 4.02 (A-6), 3.86 (G-5), 3.83 (A-6′), 3.81 (G-3), 
3.80 (G-6,6′), 3.55 (G-2). 13C-NMR signals (125 MHz): 104.0 (G-1), 89.8 (A-1), 87.6 (A-4), 81.6 (A-3), 79.5 (A-2), 
77.3 (G-4), 76.3 (A-5), 75.4 (G-5), 73.4 (A-6), 72.4 (G-3) 71.7 (G-2), 61.7 (G-6).
Generation of a κ/ι-carrabiose mixture. Starting from the alkali treated κ/ι-hybrid carrageenan from 
cystocarpic Iridaea undulosa, and following the procedure stated in Section 2.6, a mixture of κ- and ι-carrabiose 
was obtained in a 9:1 ratio (as determined by 1H-NMR, Fig. 2A).
Figure 1. Pathway for the preparation of the different compounds. In gray, the compounds assessed.
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Generation of κ-carrabiitol and its triethylamonium salt. Impure κ-carrabiose (20 mg) was treated 
with 5 mg NaBH4 and 10 ml of 1 M NH4OH. The reaction was left overnight. Then, the ammonia was evaporated 
at reduced pressure. The solid was redissolved in water and reevaporated three times. Finally, the solid was dis-
solved in 1 ml of water and purified as described in Section 2.6, obtaining κ-carrabiitol (Fig. 2A). 1H-NMR signals 
Figure 2. Polysaccharides, oligosaccharides and disaccharides: structures and characterization. (A) Chemical 
structures of κ-carrageenan and its degraded product, ι-carrageenan, λ-carrageenan and its degraded product, 
κ-carrabiose, ι-carrabiose, κ-carrabitol, ι-carrabiitol and α-carrabiitol. (B) 500 MHz 1H-NMR spectra of 
κ-carrageenan and its oligosaccharides in D2O: (a) undegraded κ-carrageenan, (b) degraded κ-carrageenan 
(n = 25.5), (c) degraded κ-carrageenan (n = 6.5), (d) impure κ-carrabiose, (e) κ-carrabiose, and f) κ-carrabiitol.
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(500 MHz, Fig. 2Bf): 4.67 (G-4), 4.54 (G-1), 4.50 (A-5), 4.18 (A-4), 4.00 (A-6), 3.91 (A-3), 3.87 (G-5), 3.87 (A-2), 
3.86 (A-6′), 3.81 (G-6,6′), 3.79 (G-3), 3.70 (A-1), 3.64 (A-1′), 3.55 (G-2). 13C-MNR signals (125 MHz): 104.1 
(G-1), 88.3 (A-4), 84.1 (A-3), 77.3 (G-4), 76.5 (A-5), 75.4 (G-5), 72.4 (G-3), 72.1 (A-2), 73.5 (A-6), 71.6 (G-2), 63.5 
(A-1), 61.8 ppm (G-6).
The product was then converted into its triethylamonium salt eluting 10 mg of the carrabiitol (dissolved in 
1 ml) through an Amberlite IR-120 resin (Et3NH+ form). The salt was obtained by freeze-drying.
Generation of a κ/ι-carrabiitol mixture. Using the protocol described in section 2.9, and the carrabiose 
mixture described in section 2.8, a κ-/ι-carrabiitol mixture (ratio 9:1) was obtained.
Generation of α-carrabiitol. α-Carrabiitol (Fig. 2A, determined by 1H-NMR) was generated as described 
for production of κ-carrabiitol (Section 2.6 and 2.9) starting from the alkali treated product of λ-carrageenan, 
carried out as reported previously for the κ/ι-hybrid from I. undulosa (Section 2.2). 1H-NMR signals (500 MHz): 
4.55 (A-2), 4.53 (G-1), 4.49 (A-5), 4.34 (A-4), 4.12 (A-3), 4.02 (A-6), 3.92 (G-4), 3.87 (A-1,1′), 3.84 (A-6′), 3.76 
(G-6,6′), 3.74 (G-5), 3.67 (G-3), 3.53 (G-2). 13C-NMR signals (125 MHz): 104.0 (G-1), 87.1 (A-4), 82.4 (A-3), 78.6 
(A-2), 76,7 (A-5), 76.1 (G-5), 73.5 (A-6), 73.4 (G-3), 71.6 (G-2), 69.4 (G-4), 61.8 (G-6), 61.3 (A-1).
Gel permeation chromatography. GPC analysis was performed with a high performance liquid chro-
matography system equipped with a Shimadzu refractive index detector (Model RID-10A), and a Shimadzu 
LC-20AT pump. Polysaccharides were analyzed using two columns connected in series: a Supelco Progel-TKS 
G4000 and a Waters Ultrahydrogel 250 (300 × 7.8 mm). A degassed solution of 0.05 M NaNO3 prepared with 
ultra-pure water containing 0.02% NaN3 was used as solvent and eluent. One hundred μl of polysaccharide solu-
tions (5 mg/ml) were filtered through a 0.22 μm PVDF membrane (GV, Millipore) and injected into the column 
using a manual valve. The eluent flow rate was of 0.6 ml/min and the temperature was held at 25 °C. The column 
was calibrated using dextran standards of different molecular weights (Sigma Aldrich, USA).
Nuclear magnetic resonance (NMR). The NMR spectra to analyze the structures and the composition 
of each mixture, were obtained on a Bruker Avance II 500 spectrometer at 500.13 (1H) and 125.77 (13C) MHz 
provided with a 5-mm probe, at room temperature, using ca. 20 mg polysaccharide in 0.7 ml of D2O. Acetone was 
added as internal standard (referred to Me4Si by calibrating the acetone methyl group to 31.1 ppm in 13C, 2.22 
ppm in 1H). 1H NMR spectra were carried out with an acquisition time of 4.36 s, a pulse angle of 30°, and a pulse 
delay of 1 s.
Cell lines. LM2 cell line derived from the murine mammary adenocarcinoma, M231, was obtained from 
Instituto Roffo, Buenos Aires, Argentina. A panel composed of the following lines was also used: IGROV-1: 
human ovarian cancer; K562: Myelogenous leukemia cell line of the erythroleukemia type; B16-F10: mouse mel-
anoma; MB49: mouse bladder cancer; A549: human bronchioloalveolar lung carcinoma and PAM212: murine 
cutaneous squamous cell carcinoma.
The cell lines (except for LM2) were obtained from the American Type Culture Collection (ATCC), USA. All 
the cells were maintained in RPMI-1640 medium supplemented with 5% serum for LM2 and 10% for the rest of 
the cells, 80 μg gentamycin/ml and 2 mM L-glutamine and kept in humidified atmosphere of 5% CO2 at 37 °C.
MTT viability assay. Cell viability was assessed by the MTT assay32, which is a method based on the activity 
of mitochondrial dehydrogenases. Following appropriate treatments, a MTT solution was added to each well in 
a concentration of 0.5 mg/ml, and plates were incubated at 37 °C for 1 h. The resulting formazan crystals were 
dissolved in dimethyl sulfoxide and the absorbance was read at 560 nm.
The concentrations required to inhibit cell growth by 50% (IC50) were calculated from the abscissa intercept 
from logistic curves constructed by plotting cell survival (%) versus drug concentration (mg/ml).
Determination of κ-carrabiose cellular uptake. With the aim of determining the likelihood of the 
involvement of active transport on the incorporation of κ-carrabiose to the cells, LM2 cells were exposed to 
κ-carrabiose (2 mg/ml) either at 4 °C or 37 °C during 90 min, time at which no cytotoxicity is induced by low 
temperature exposure33. Afterwards, MTT assay was routinely performed as described in 2.15.
Cell cycle distribution. Cells (7 × 104 cells/ml) were seeded in a 12 well plate, 24 h later κ-carrabiose was 
added and another 48 h later, the cells were tripsinized and centrifuged with the conditioned media, and the pellet 
was resuspended with 70% ethanol to fix the cells. Cells were exposed to ethanol at 4 °C for 30 min and washed 
in 2% bovine serum albumin in phosphated buffered saline. The pellets were incubated with 0.3 ml of 100 µg/ml 
RNAase during 30 min and then 50 µl of 1 mg/ml propidium iodide was added to stain DNA just before the 
cytometric analysis. The cell-cycle phase distribution was determined using a BD FACSCalibur flow cytometer 
(Becton Dickinson, San Jose, CA). The percentages of cells in each cell-cycle phase were analyzed using FlowJo 
vX software. Toxicity was checked by MTT viability assay in parallel experiments.
Immunofluorescence assays for expression of cell-cell adhesion and cell-substrate adhesion 
proteins. To visualize the expression of the cell-cell adhesion proteins E-cadherin and β-catenin and the 
cell-matrix adhesion protein vinculin, immunofluorescence assays were carried out. LM2 cells (1 × 105 cells/ml) 
grown on coverslips were fixed in 4% paraformaldehyde for 15 min. Samples were rehydrated in PBS, permea-
bilized with 1% Triton X-100 in PBS for 10 min and incubated with the anti E-cadherin, β-catenin or vinculin 
primary antibody for 1 h at 37 °C, washed with PBS, incubated with a FITC-labelled secondary antibody (1:500 
in 0.1% BSA) and finally washed with PBS. The preparations were mounted in ProLong Gold antifade reagent 
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(Invitrogen, USA). Microscopic observation and photography were performed with an Olympus photomicro-
scope BX51, equipped with a HBO 100 W mercury lamp and the green filter sets for fluorescence microscopy 
(545 nm, exciting filter BP 545).
In vitro migration assay. Cell migration was determined using a wound healing assay. An amount of 
2 × 105 cells were plated in complete medium containing 10% fetal bovine serum into 6-multiwell plates and 
allowed to grow until confluence, time at which the cultures were wounded through the central axis with a sterile 
200 μl tip. Cells were washed with PBS, refreshed with serum containing medium and incubated with different 
concentrations of κ-carrabiose. After overnight incubation (21 h) at 37 °C cells were fixed, stained with Crystal 
violet and photographed. Quantification of cell motility was performed by measuring the distance between the 
invading fronts of cells in six random selected microscopic fields for each condition. The degree of motility was 
expressed as a migration index (MI = (0 h wound − 24 h wound)/0 h wound). Images were acquired with an 
Olympus microscope with 10X objective and processed using image processing software.
Statistical analysis. Values were expressed as mean ± standard deviations of the mean. Analysis of var-
iance (ANOVA) with post hoc comparisons was used to determine statistical significance employing the raw 
non-relativized data (Graphpad Instat© software).
Results and Discussion
Analysis of cytotoxicity. In the present work we selected a tumor cell line for this preliminar cytotoxicity 
screening and to gain insight into the use of carrageenans as potential antitumor agents. Since the use of normal 
cell populations as controls proved not to be feasible on the screening of anticancer drugs34 we did not attempt to 
carry out any comparison between normal and tumor cell lines.
Polysaccharides. There are three main types of carrageenans, differentiated by the position and degree of sul-
fation and the presence or absence of 3,6-anhydrogalactose. κ-Carrageenan is composed of alternating 3-linked 
β-d-galactopyranose 4-sulfate and 4-linked 3,6-anhydro-α-d-galactopyranose units, thus having one negative 
charge per disaccharide repeating unit (Fig. 2A); ι-carrageenan has the same backbone but an additional sulfate 
group at C-2 of the α- unit (Fig. 2A), whereas λ-carrageenan has no 3,6-anhydrogalactose and carries three 
sulfate groups per disaccharidic unit (at C-2 of the β- unit and at C-2 and C-6 of the α- unit, Fig. 2C). The actual 
polysaccharides show small deviations from the ideal structures depicted in the Figures.
With the aim to establish the cytotoxicity of carrageenans, we exposed LM2 tumor cells to the different carra-
geenans and assessed cell viability.
The first step was to evaluate the native κ-, ι- and λ-carrageenans. Figure 3A shows that κ- and ι-carrageenan 
have similar cytotoxic capacity, with IC50 values of 0.23 ± 0.02 and 0.20 ± 0.04 mg/ml respectively, inducing 
Figure 3. Cytotoxicity of carrageenan polysaccharides (A), oligosaccharides (B), carrabioses (C) and 
carrabiitols (D) in LM2 cells. LM2 cells were exposed to the compounds at different concentrations, during 48 h 
and afterwards, cell viability was quantified by the MTT assay. Cell death is referred as percentage of the vehicle 
treated control.
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significant reduction of cell death respect to the control from 0.1 mg/ml onwards (p < 0.01, ANOVA, Dunnet 
post hoc test). On the other hand, λ-carrageenan only showed significant toxicity at 1 mg/ml. The presence of a 
higher number of sulfate groups in the disaccharidic unit appears to be correlated with a neglected cytotoxicity.
Certain cytotoxicity of compounds κ- and λ-carrageenans on Hela cells has already been reported, showing 
IC50 values of 0.55 and 0.47 mg/ml respectively after 72 h exposure14. We obtained a lower IC50 (0.23 mg/ml) upon 
48 h incubation with κ-carrageenan but we did not find cytotoxicity at all for λ-carrageenan. This last result is 
consistent with the findings of Zhou et al.12, as they observed that λ-carrageenan is active in vivo, but not in vitro. 
Furthermore, other authors reported scarce cytotoxicity of undegraded carrageenans18,21. In the present work we 
have found, that besides κ-carrageenan, ι-carrageenan is also cytotoxic.
The differences observed between our results and those obtained by other authors may be based on the dif-
ferences in terms of different susceptibilities of a given cancer type for any particular drug35, time exposure and 
serum percentage employed.
Li et al.15 reported that λ-carrageenan might act as an antitumor agent by modulating the immune response, 
i.e. an indirect effect of cell killing, promoting dendritic cells maturation and thus they proposed its use as an 
adjuvant of dendritic cell -based vaccines.
To the best of our knowledge, there are no previous reports of ι-carrageenan as a potential antitumor com-
pound. Ariffin et al.21 studied the effect of κ- and ι-carrageenans in normal and cancerous intestine and liver 
human cell lines, and they did not show cytotoxicity effect in their experimental system.
Regarding the degradation products of carrageenans, Jin et al.20 demonstrated the in vitro antitumor activity 
of degraded ι-carrageenan against an osteosarcoma cell line, but ours is the first report of potential antitumoral 
activity of a non-degraded ι-carrageenan.
We could hypothesize a possible relationship between the structure of the compounds and their cytotoxicity, 
being the most active compounds κ- and ι-carrageenan, which contain less sulfate groups, thus suggesting that 
an abundance of these groups could contribute to lower its cytotoxic action. This is not surprising, since the pres-
ence of anionic ions would be lowering the interactions between the carrageenan and the cells, considering that 
membranes bear negative charges.
Oligosaccharides. In a second step, we hydrolyzed partially a cytotoxic (κ-carrageenan) and a non-cytotoxic 
(λ-carrageenan) polysaccharide, thus generating chemically characterized oligosaccharides that were evaluated 
under the same conditions. Figure 3B shows that the κ-oligosaccharides exert cytotoxicity within the same IC50 
range as compared to the polysaccharides. Degraded κ-carrageenans with n = 25.5 and 6.5 show IC50 values of 
0.39 ± 0.05 and 0.38 ± 0.04 mg/ml respectively, this toxicity being significantly higher than that found in for the 
undegraded κ-carrageenan (p < 0.01, ANOVA, followed by Tukey post hoc test), in spite of the reported fact 
indicating that degradation of the polysaccharides increase the cytotoxicity12,21.
On the other hand, the degraded λ-carrageenan (n = 43.2) presents a marked cytotoxicity (IC50 = 0.95 ± 0.11 mg/ml), 
much higher as compared to the parent polysaccharide (p < 0.01, ANOVA, followed by Tukey post hoc test), thus 
demonstrating that, in this case, partial hydrolysis of the polysaccharide improved its cytotoxic properties.
There are previous reports of the antitumor properties of degraded κ-carrageenans18,21,36 but to date there are 
no reports of cytotoxicity of a degraded λ-carrageenan in vitro.
Disaccharides and disaccharide-alditols. We have further continued the study with even smaller compounds, 
through modifications and purification (Fig. 1), which led to different disaccharides (carrabioses, Fig. 3C) or 
mixtures. The structures of the purified carrabioses, in particular, were confirmed by NMR spectroscopy (full 
assignment is shown in the Materials and Methods section). Data for κ-carrabiose is consistent with literature37, 
although to the best of our knowledge, data for ι-carrabiose has never been reported before. NMR data showed 
that carrabioses carry a masked aldehyde group in the form of a hydrate.
The carrabioses present a broad range of cytotoxicity values upon tumor cells. Figure 3C indicates that among 
the carrabioses, pure κ-carrabiose and the mixture 9:1 of κ- and ι-carrabiose are the most cytotoxic compounds 
(significantly higher than ι-carrabiose alone (p < 0.05, ANOVA, Tukey post hoc test), having IC50 values of 
0.043 ± 0.009 mg/ml and 0.052 ± 0.005 mg/ml respectively, thus suggesting again the influence of the low sulfa-
tion degree on the toxicity of these compounds.
Among κ-carrabioses, the pure compound is more cytotoxic than the impure one, whereas among 
ι-carrabioses, the impure is more active (p < 0.05, ANOVA, Tukey post hoc test). IC50 values are as follows: 
0.074 ± 0.009 mg/ml for impure κ-carrabiose, 0.183 for ± 0.015 mg/ml and 0.338 ± 0.035 mg/ml for impure and 
pure ι-carrabiose, respectively and 0.133 ± 0.012 mg/ml for the 3:1 mixture of κ- and ι-carrabiose.
These results indicate that depolymerization up to the disaccharide increases the cytotoxicity of the carbohy-
drates, at least for κ-carrageenan. It is also clear that κ-carrabiose shows a higher cytotoxicity than ι-carrabiose, 
suggesting that this capacity is not favored by sulfation on C-2 of the 3,6-anhydro sugar. As expected, the mix-
tures of of κ- and ι-carrabioses have intermediate IC50 values, suggesting that no synergistic effect between both 
disaccharides occur.
The presence of an aldehyde group (masked as a hydrate) in carrabioses generates a biological activity that is 
lost when these disaccharides are reduced to their alditols (carrabiitols), since the sulfate content is the same in 
both compounds. Both α- and κ-carrabiitol have also been analyzed by NMR spectroscopy (full assignment is 
shown in the Material and Methods section; data is consistent with literature38) and the purified products were 
tested for cytotoxicity. All the samples show no cytotoxicity at all (Fig. 3D), suggesting that the masked aldehyde 
group is key for keeping the cytotoxic activity.
It has been found that short chain aldehydes are hard electrophiles that cause toxicity, probably by forming 
adducts with hard biological nucleophile, e.g., primary nitrogen groups39 of proteins or nucleic acids.
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It is worth to note that to the best of our knowledge, there are not any previous reports of the antitumoral activ-
ity of disaccharides derived from carrageenans identified and tested as antitumoral agents. Besides, κ-carrabiose 
has an IC50 10–30 times lower than those of other oligosaccharides derived from carrageenans found in literature, 
even after longer exposition to the compounds14,18,20.
The IC50 of κ-carrabiose is near 100 μM, within the range of several antineoplasics commonly used tested 
under the same conditions of incubation time. Simon et al.40 established cell cultures from 30 mammary gland 
tumors excised from dogs and reported the following IC50 values for chemotherapeutics after incubation during 
48 h: 0.34 μM for doxorubicin; 27.3 μM for cisplatin and 53.4 μM for carboplatin. Our results are highly encourag-
ing, although further in vivo studies are needed to test the potential of this disaccharide as an antineoplasic agent. 
κ-Carrageenan should not be used in injectable form due to its anticoagulation properties1,8. On the other hand, 
κ-carrabiose, which does not have this property due to its low molecular weight, could be a potential agent for 
parenteral administration.
Purified κ-carrabiose was the compound exerting the highest cytotoxicity against LM2 tumor cells, and thus 
we selected this disaccharide for the following studies about its potential antitumor ability.
Analysis of cytotoxicity of κ-carrabiose in different cell lines. The cytotoxicity of the most promising 
compound (i.e. κ-carrabiose) was additionally evaluated in a small panel of tumor cell lines of various origins 
such as ovary, blood and lung cancer, melanoma, squamous cell carcinoma, and leukemia. LM2 cells data is also 
included (Table 1). In the new cell lines evaluated, the obtained IC50 values ranging from 0.051 to 0.099 mg/ml, 
thus showing that κ-carrabiose is potentially cytotoxic in several tissues besides mammary.
Effect of purified κ-carrabiose on the LM2 cell cycle. Figure 4 shows the analysis of cell cycle after 
propidium iodide staining of DNA of LM2 cells treated with purified κ-carrabiose. At concentrations higher than 
the IC50, such as 0.06 mg/ml, we observed an increase in the sub-G1 cell population (5.3%, control, vs. 21.3%), 
thus showing an increase in apoptotic cell death.
In addition, LM2 cells exposed to κ-carrabiose employed at 0.06 mg/ml, showed an increased arrest in S phase 
(6.2 to 13.6%) and a corresponding decrease of cells in the G1 and G2-M phases as compared to the control.
Cell death is typically discussed dichotomously as either apoptosis or necrosis. Apoptosis is described as an 
active, programmed process of autonomous cellular dismantling that avoids eliciting inflammation. Necrosis has 
been characterized as passive, accidental cell death resulting from environmental perturbations with uncontrolled 
release of inflammatory cellular contents. As apoptosis is considered to be a regulated and controlled process41, it 
is desirable that new compounds are able to elicit cell death via apoptosis42.
Most antineoplasics such as 5-fluorouracil, methotrexate, docetaxel, hydroxyurea etc, exert their action 
through apoptotic death of target cells as well as arrest in S phase43–45, similarly to the mechanism driven by the 
purified κ-carrabiose.
Cellular mechanism of κ-carrabiose uptake. Mammalian cells are generally considered to be unable to 
employ polysaccharides for cell growth because the phospholipid bilayer in the cell membrane has very low per-
meability to sugars. This is not surprising, since there is only one known animal disaccharide sucrose transporter 
that was recently reported46. With the aim of determining if κ-carrabiose was being incorporated into the cells, 
we studied the influence of temperature on the uptake period of the disaccharide. Passive transport processes 
are typically assessed in a parallel incubation at 4 °C to disable any active transport proteins47. For that purpose, 
we exposed LM2 confluent cells to the maximum possible κ-carrabiose concentration (2 mg/ml). Under these 
conditions, no differential cytotoxicity was observed, thus suggesting that κ-carrabiose is not being incorporated 
into the cells at all or either being transported by passive diffusion, which is an unlikely mechanism possible for 
a disaccharide.
Effects of purified κ-carrabiose on cell-cell and cell-substrate adhesion of LM2 cells. Figure 5 
shows the impact of κ-carrabiose on the intracellular distribution of the cell-cell adhesion proteins E-cadherin 
and β-catenin and the cell-substrate adhesion protein vinculin. While LM2 control cells exhibited a nor-
mal E-cadherin distribution at the cell-to-cell interface, this distribution was disrupted in cells treated with 
κ-carrabiose and its expression resulted aberrant, with interdigitations appearing along the cell-cell interface 
together with a diffuse cytoplasmic signal. This pattern of distribution, accounts for higher cell–cell cohesion 
suggests and a higher cell differentiation level and thus a decrease in tumorigenesis48.
Cell line CI50 (mg/ml)
LM2 0.043 ± 0.009
IGROV-1 0.099 ± 0.004
K562 0.049 ± 0.002
B16-F10 0.039 ± 0.005
MB49 0.045 ± 0.008
A549 0.066 ± 0.005
Pam212 0.051 ± 0.006
Table 1. Cytotoxicity of κ-carrabiose in a panel of cell lines expressed as IC50 (mg/ml) after 48 h exposure in 5% 
serum-containing medium, Mean ± SD.
9Scientific RepoRts |          (2019) 9:6654  | https://doi.org/10.1038/s41598-019-43238-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Similarly, β-catenin staining suggests an aberrant distribution after κ-carrabiose treatment. Whereas localiza-
tion in the cell-cell contact areas is absent, a re-localization in the nucleus is present.
Two main groups of adhesion molecules: cadherins and cell-matrix adhesion molecules, have been implicated 
in tumor malignancy. However, the specific role that these proteins play in the context of tumor progression 
remains to be elucidated49. Beta-catenin was first identified at adherens junctions where it links cadherins with 
the cytoskeleton to regulate the response to cell adhesion. In addition, a small yet dynamic pool of β-catenin 
shuttles rapidly between the cytoplasm and nucleus50 and is responsible for transducing signals from plasma 
membrane to the nucleus, being an important step in cancer progression51.
In addition, vinculin distribution was confined to the focal adhesion points in LM2 control cells, whereas in 
κ-carrabiose treated cells a diffuse cytoplasmic pattern was observed. Vinculin provides a mechanical link con-
trols cell signalling processes, affects contractility and adhesion protein turnover. Vinculin has been suggested 
to function as a tumour suppressor by supporting anchorage-dependent cell growth and by suppressing tumour 
metastasis through reducing cell motility, but this depends on the dimensionality, adhesiveness or steric hin-
drance of the environment52. However, as has previously found by our group48, vinculin expression in the focal 
contacts of the LM2 treated cells appears not to have a positive impact on cell migration.
In summary, κ-carrabiose affects cell–cell and cell-substrate adhesion of LM2 tumor cells through the topo-
graphic reorganization of some cytoskeletal and adhesion proteins, and these changes may be related to a differ-
ential cell migration observed in vitro in a wound assay.
The in vivo antitumor activity of carrageenans reported elsewhere10 has been hypothesized to be related to 
the destabilization of the interaction of the GAGs portion of the proteoclycans and the extracellular matrix pro-
teins11. However, there are no previous reports on carrageenans or its derived disaccharides action on cell-to-cell 
Figure 4. Influence of κ-carrabiose on LM2 cell cycle. LM2 cells were incubated with κ-carrabiose, at different 
concentrations, during 48 h and afterwards, the DNA was stained with propidium iodide and cell cycle was 
analyzed by flow cytometry as described in Materials & Methods. (A) The histograms show the number of cells 
(events) in each phase of the cell cycle. FL-area denotes propidium iodide fluorescence; (B) the Table shows the 
percentage of cells in each phase of the cycle and the correlation with the number of living cells determined by 
the MTT assay.
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interactions or on cell-substrate or extracellular matrix adhesion. However, normal adhesion process related to 
vinculin in B16 tumoral cells was altered when were seeded on sulfonated-chitosan films, which could reflect a 
possible in vivo delay on metastatic cell adhesion53.
Effect of purified κ-carrabiose on the migratory ability of LM2 cells. Tumor metastasis is the most 
common cause of death in cancer patients. In carcinomas, the metastatic process is thought to consist of a number 
of distinct steps, invasion, intravasation, extravasation and proliferation. In the first step cells lose cell-cell adhe-
sion and gain motility, which enables them to invade the adjacent tissue54.
The first step of the metastatic cascade is the ability of cells to migrate and reach a blood vessel to intravasate 
and invade distant organs. Therefore, we tested the ability of LM2 tumor cells treated with purified κ-carrabiose 
to migrate and close an experimental wound (Fig. 6). It was shown that the strong migratory capacity of the 
non-treated cells was dramatically impaired in the cells pretreated with purified κ-carrabiose in all the concen-
tration range assayed. In addition, a correlation between the the migratory decrease and the concentration of 
purified κ-carrabiose was also noticed. At 0.05 mg/ml, migration index was equal to: 0.52 ± 0.07. These results 
suggest that the cells surviving κ-carrabiose treatment would have a reduced ability to colonize distant organs, 
which is also important in terms of an effective anticancer treatment.
The highest concentration employed, that is 0.1 mg/ml, was not considered in the analysis since the cytotoxic 
effect, which is clearly observed in the Figure, does not allow us to evaluate the migratory ability.
Conclusions
In this novel study of carrageenans and their derived oligosaccharides (see Fig. 7), we found that the presence 
of sulfate groups is a factor abrogating its potential cytotoxicity of native carrageenans, thus being the κ- and 
ι-carrageenans the more active agents among the polysaccharides.
In addition, some oligosaccharides are more cytotoxic than their parent compounds, thus showing that the 
lower molecular weight is one of the factors that improves its cell death killing ability. We have also focused on the 
study of the disaccharides obtained as degradation products of the carrageenans and their reduction products. 
None of the carrabiitols tested showed any significant cytotoxicity. Carrabioses, on the contrary, show the highest 
Figure 5. Effects of κ-carrabiose on cell-cell and cell-substrate adhesion of LM2 cells. Exemplary photographs 
of E-cadherin, β-catenin and vinculin immunofluorescence staining (detailed in Materials and Methods) after 
48 h exposure to κ-carrabiose. Control cells exposed to vehicle were included. 100X magnification.
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Figure 6. Wound healing assay of LM2 incubated with κ-carrabiose. Confluent LM2 monolayers were gently 
wounded and incubated in the presence of concentrations of κ-carrabiose. (A) After overnight incubation in 
presence of the compound (21 h) microscope photographs were taken. Controls of time 0 were carried out 
immediately after wounding; (B) Quantification of cell motility was carried out by measuring the distance 
between the invading fronts of cells in six random selected microscopic fields and the degree of motility was 
expressed as the Migration Index as detailed in Materials and methods. *p < 0.05, 1-way ANOVA test followed 
by Tukey post hoc test.
Figure 7. Summarized scheme of the results.
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cytotoxic responses against tumor cells, being pure κ-carrabiose the most active of all the tested compounds. and 
thus we hypothesize that the aldehyde group could be the responsible for its biological activity.
We showed that this compound induces cell death through induction of G2/M phase arrest and apopto-
sis, changes on cell-cell and cell-matrix interactions probably exerting its action from outside the cells and thus 
potentially impairing the metastasizing ability of the surviving LM2 cells, suggesting a potential as an antitumor 
agent.
Potential applications of the results emerging from the present work include the use of disaccharide units such 
as carrabioses coupled to antineoplasics in order to improve its cytotoxicity and antimetastatic properties, and the 
use of ι-carrageenan as adjuvant or carrier in anticancer treatments. However, further studies extrapolating these 
results in vivo experiments are needed to assess carrabioses (and especially κ-carrabiose) as potential antitumor 
agents.
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